Delivery Order SPE2DB20D2104-SPE2DB21FR32T
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,854.80 delivery order contract is for the Prime Vendor Pharmaceutical Branch in Philadelphia, with a completion date of September 2, 2020. Amerisourcebergen, a subsidiary of the parent company Cencora, Inc., holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide a Prime Vendor Pharmaceutical Branch in Philadelphia. The contract, valued at $1,750.12, is a Firm Fixed Price Delivery Order without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,532.58, is a delivery order for a "Prime Vendor Pharm Branch-Philadelphia," indicating the supply of pharmaceutical products and medical supplies. The award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA...
- This federal contract award is for a Prime Vendor Pharmaceutical Branch-Philadelphia delivery order valued at $4,632.00, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a performance period through May 20, 2021 and is a firm fixed price delivery order. Amerisourcebergen, through its parent company Cencora, Inc., holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,067.79, is for a Prime Vendor Pharmaceutical Branch in Philadelphia, with an ultimate completion date of April 16, 2021. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,374.53, is a delivery order for "PRIME VENDOR PHARM BRANCH-PHILADELPHIA" and has a completion date of February 24, 2021. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award is for a pharmaceutical prime vendor arrangement between the Defense Logistics Agency (DLA) and Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,640.40, is a delivery order under a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Cencora, Inc. (parent company of Amerisourcebergen) worth up to $999,999,999.00. This IDC serves as the primary vehicle for Amerisourcebergen to provide a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,513.04 delivery order contract is a firm fixed-price agreement for the Prime Vendor Pharmaceutical Branch in Philadelphia, with a period of performance through May 18, 2021. Amerisourcebergen, a subsidiary of the parent company Cencora, Inc., holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,556.60, is a delivery order under the Prime Vendor Pharmacy Branch-Philadelphia program. It covers the delivery of a wide range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide a Prime Vendor Pharmaceutical Branch in Philadelphia. The contract has a ceiling value of $1,482.60 and runs through November 2020. It is a Firm Fixed Price Delivery Order contract that covers the supply of a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB21FR32TDelivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,441.44, is for a delivery order to provide a Prime Vendor Pharmaceutical Branch-Philadelphia. The contract has no set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 12/18/20 |